image
Amylyx Pharmaceuticals, Inc. AMLX
Healthcare - Biotechnology - NASDAQ - US
Watchlist
$ 5.17
2.64 %
$ 461 M
Market Cap
-1.63
P/E
1. INTRINSIC VALUE

This DCF valuation model was last updated on Jun, 6, 2025.

The intrinsic value of one AMLX stock under the worst case scenario is HIDDEN Compared to the current market price of 5.17 USD, Amylyx Pharmaceuticals, Inc. is HIDDEN

AMLX Intrinsic Value
HIDDEN
SHOW

This DCF valuation model was last updated on Jun, 6, 2025.

The intrinsic value of one AMLX stock under the base case scenario is HIDDEN Compared to the current market price of 5.17 USD, Amylyx Pharmaceuticals, Inc. is HIDDEN

AMLX Intrinsic Value
HIDDEN
SHOW

This DCF valuation model was last updated on Jun, 6, 2025.

The intrinsic value of one AMLX stock under the best case scenario is HIDDEN Compared to the current market price of 5.17 USD, Amylyx Pharmaceuticals, Inc. is HIDDEN

AMLX Intrinsic Value
HIDDEN
SHOW
2. FUNDAMENTAL ANALYSIS

Price Chart AMLX

image
1M -7.0%
6M 24%
1Y 213%
3Y -250%
5Y --%
All
$6.0$6.0$5.5$5.5$5.0$5.0$4.5$4.5$4.0$4.0$3.5$3.5$3.0$3.015 Dec15 DecJan '25Jan '2515 Jan15 JanFeb '25Feb '2515 Feb15 FebMar '25Mar '2515 Mar15 MarApr '25Apr '2515 Apr15 AprMay '25May '2515 May15 MayJun '25Jun '25
FINANCIALS
87.4 M REVENUE
-77.06%
Growth Rates
1Year -77.06%
3Years 574.28%
5Years 127.75%
7Years 0.00%
10Years 0.00%
-315 M OPERATING INCOME
-811.12%
Growth Rates
1Year -811.12%
3Years -56.13%
5Years -87.57%
7Years 0.00%
10Years 0.00%
-302 M NET INCOME
-612.42%
Growth Rates
1Year -612.42%
3Years -50.83%
5Years -85.56%
7Years 0.00%
10Years 0.00%
-168 M OPERATING CASH FLOW
-1406.55%
Growth Rates
1Year -1406.55%
3Years -30.87%
5Years -73.42%
7Years 0.00%
10Years 0.00%
75.7 M INVESTING CASH FLOW
-17.81%
Growth Rates
1Year -17.81%
3Years 53.69%
5Years 0.00%
7Years 0.00%
10Years 0.00%
348 K FINANCING CASH FLOW
-90.18%
Growth Rates
1Year -90.18%
3Years -87.00%
5Years -12.23%
7Years 0.00%
10Years 0.00%
0 REVENUE
100.00%
Growth Rates
1Year -77.06%
3Years 574.28%
5Years 127.75%
7Years 0.00%
10Years 0.00%
-37.8 M OPERATING INCOME
7.01%
Growth Rates
1Year -811.12%
3Years -56.13%
5Years -87.57%
7Years 0.00%
10Years 0.00%
-35.9 M NET INCOME
4.37%
Growth Rates
1Year -612.42%
3Years -50.83%
5Years -85.56%
7Years 0.00%
10Years 0.00%
-39.8 M OPERATING CASH FLOW
32.51%
Growth Rates
1Year -1406.55%
3Years -30.87%
5Years -73.42%
7Years 0.00%
10Years 0.00%
-43.7 M INVESTING CASH FLOW
-67.19%
Growth Rates
1Year -17.81%
3Years 53.69%
5Years 0.00%
7Years 0.00%
10Years 0.00%
65.7 M FINANCING CASH FLOW
59592.73%
Growth Rates
1Year -90.18%
3Years -87.00%
5Years -12.23%
7Years 0.00%
10Years 0.00%
Balance Sheet Amylyx Pharmaceuticals, Inc.
image
Current Assets 189 M
Cash & Short-Term Investments 177 M
Receivables 447 K
Other Current Assets 12.5 M
Non-Current Assets 4.2 M
Long-Term Investments 0
PP&E 2.73 M
Other Non-Current Assets 1.47 M
91.15 %6.45 %Total Assets$193.6m
Current Liabilities 28.4 M
Accounts Payable 2.94 M
Short-Term Debt 1.52 M
Other Current Liabilities 23.9 M
Non-Current Liabilities 463 K
Long-Term Debt 463 K
Other Non-Current Liabilities 0
10.18 %5.26 %82.96 %Total Liabilities$28.9m
EFFICIENCY
Earnings Waterfall Amylyx Pharmaceuticals, Inc.
image
Revenue 87.4 M
Cost Of Revenue 42.2 M
Gross Profit -37.3 M
Operating Expenses 360 M
Operating Income -315 M
Other Expenses -13 M
Net Income -302 M
100m100m50m50m00(50m)(50m)(100m)(100m)(150m)(150m)(200m)(200m)(250m)(250m)(300m)(300m)(350m)(350m)(400m)(400m)87m(42m)(37m)(360m)(315m)13m(302m)RevenueRevenueCost Of RevenueCost Of RevenueGross ProfitGross ProfitOperating ExpensesOperating ExpensesOperating IncomeOperating IncomeOther ExpensesOther ExpensesNet IncomeNet Income
RATIOS
-42.65% GROSS MARGIN
-42.65%
Averages
1Year -42.65%
3Years 45.74%
5Years -692.95%
7Years 0.00%
10Years 0.00%
-360.22% OPERATING MARGIN
-360.22%
Averages
1Year -360.22%
3Years -418.58%
5Years -7253.97%
7Years 0.00%
10Years 0.00%
-345.36% NET MARGIN
-345.36%
Averages
1Year -345.36%
3Years -408.26%
5Years -7791.51%
7Years 0.00%
10Years 0.00%
-183.14% ROE
-183.14%
Averages
1Year -183.14%
3Years -76.67%
5Years -20.94%
7Years 0.00%
10Years 0.00%
-155.83% ROA
-155.83%
Averages
1Year -155.83%
3Years -65.66%
5Years -119.62%
7Years 0.00%
10Years 0.00%
-188.50% ROIC
-188.50%
Averages
1Year -188.50%
3Years -79.46%
5Years -188.47%
7Years 0.00%
10Years 0.00%
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis Amylyx Pharmaceuticals, Inc.
image
20m20m00(20m)(20m)(40m)(40m)(60m)(60m)(80m)(80m)(100m)(100m)(120m)(120m)(140m)(140m)(160m)(160m)(180m)(180m)(200m)(200m)202020202021202120222022202320232024202420252025
Net Income -302 M
Depreciation & Amortization 904 K
Capital Expenditures -157 K
Stock-Based Compensation 33 M
Change in Working Capital 0
Others 146 M
Free Cash Flow -168 M
3. WALL STREET ANALYSTS ESTIMATES
Wall Street Analysts Price Targets Amylyx Pharmaceuticals, Inc.
image
Wall Street analysts predict an average 1-year price target for AMLX of $8.6 , with forecasts ranging from a low of $4 to a high of $11 .
AMLX Lowest Price Target Wall Street Target
4 USD -22.63%
AMLX Average Price Target Wall Street Target
8.6 USD 66.34%
AMLX Highest Price Target Wall Street Target
11 USD 112.77%
Price
Max Price Target
Min Price Target
Average Price Target
11111010998877665544332211Jul '24Jul '24Aug '24Aug '24Oct '24Oct '24Nov '24Nov '2420252025Feb '25Feb '25Apr '25Apr '25Jun '25Jun '25Jul '25Jul '25Aug '25Aug '25Oct '25Oct '25Nov '25Nov '2520262026Feb '26Feb '26Apr '26Apr '26Jun '26Jun '26
4. DIVIDEND ANALYSIS
0.00% DIVIDEND YIELD
0.42 USD DIVIDEND PER SHARE
Q1
Q2
Q3
Q4
1.201.201.001.000.800.800.600.600.400.400.200.200.000.000.420.240.361.020.002017201720182018
Download SVG
Download PNG
Download CSV
5. COMPETITION
slide 2 of 8
6. Ownership
Insider Ownership Amylyx Pharmaceuticals, Inc.
image
Sold
0-3 MONTHS
262 K USD 5
3-6 MONTHS
203 K USD 3
6-9 MONTHS
213 K USD 4
9-12 MONTHS
0 USD 0
Bought
37 K USD 1
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
428 K USD 3
9-12 MONTHS
7. News
Amylyx Pharmaceuticals, Inc. (AMLX) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Contact the Firm to Learn More About the Investigation NEW YORK CITY, NY / ACCESS Newswire / June 5, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Amylyx Pharmaceuticals, Inc. ("Amylyx" or "the Company") (NASDAQ:AMLX). Investors who purchased Amylyx securities prior to November 11, 2022, and continue to hold to the present, are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/AMLX. accessnewswire.com - 2 weeks ago
Bronstein, Gewirtz & Grossman, LLC Encourages Amylyx Pharmaceuticals, Inc. (AMLX) Shareholders to Inquire about Securities Investigation NEW YORK CITY, NY / ACCESS Newswire / June 3, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Amylyx Pharmaceuticals, Inc. ("Amylyx" or "the Company") (NASDAQ:AMLX). Investors who purchased Amylyx securities prior to November 11, 2022, and continue to hold to the present, are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/AMLX. accessnewswire.com - 2 weeks ago
Amylyx Pharmaceuticals Receives U.S. FDA Fast Track Designation for AMX0114 for the Treatment of Amyotrophic Lateral Sclerosis CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $AMLX--Amylyx Pharmaceuticals Receives U.S. FDA Fast Track Designation for AMX0114 for the Treatment of Amyotrophic Lateral Sclerosis. businesswire.com - 2 weeks ago
Bronstein, Gewirtz & Grossman, LLC Is Investigating Amylyx Pharmaceuticals, Inc. (AMLX) And Encourages Shareholders to Connect NEW YORK CITY, NY / ACCESS Newswire / June 1, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Amylyx Pharmaceuticals, Inc. ("Amylyx" or "the Company") (NASDAQ:AMLX). Investors who purchased Amylyx securities prior to November 11, 2022, and continue to hold to the present, are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/AMLX. accessnewswire.com - 2 weeks ago
Bronstein, Gewirtz & Grossman, LLC Is Investigating Amylyx Pharmaceuticals, Inc. (AMLX) And Encourages Investors to Connect NEW YORK CITY, NY / ACCESS Newswire / May 29, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Amylyx Pharmaceuticals, Inc. ("Amylyx" or "the Company") (NASDAQ:AMLX). Investors who purchased Amylyx securities prior to November 11, 2022, and continue to hold to the present, are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/AMLX. accessnewswire.com - 3 weeks ago
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Amylyx Pharmaceuticals, Inc. (AMLX) and Encourages Investors to Learn More About the Investigation NEW YORK CITY, NY / ACCESS Newswire / May 25, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Amylyx Pharmaceuticals, Inc. ("Amylyx" or "the Company") (NASDAQ:AMLX). Investors who purchased Amylyx securities prior to November 11, 2022, and continue to hold to the present, are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/AMLX. accessnewswire.com - 3 weeks ago
Amylyx Pharmaceuticals, Inc. (AMLX) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation NEW YORK CITY, NY / ACCESS Newswire / May 22, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Amylyx Pharmaceuticals, Inc. ("Amylyx" or "the Company") (NASDAQ:AMLX). Investors who purchased Amylyx securities prior to November 11, 2022, and continue to hold to the present, are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/AMLX. accessnewswire.com - 4 weeks ago
Amylyx Pharmaceuticals to Participate in Upcoming June Investor Conferences CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $AMLX--Amylyx Pharmaceuticals to Participate in Upcoming June Investor Conferences. businesswire.com - 1 month ago
Wall Street Analysts See a 105.22% Upside in Amylyx Pharmaceuticals (AMLX): Can the Stock Really Move This High? The mean of analysts' price targets for Amylyx Pharmaceuticals (AMLX) points to a 105.2% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock. zacks.com - 1 month ago
Bronstein, Gewirtz & Grossman, LLC Is Investigating Amylyx Pharmaceuticals, Inc. (AMLX) And Encourages Investors to Connect NEW YORK CITY, NY / ACCESS Newswire / May 20, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Amylyx Pharmaceuticals, Inc. ("Amylyx" or "the Company") (NASDAQ:AMLX). Investors who purchased Amylyx securities prior to November 11, 2022, and continue to hold to the present, are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/AMLX. accessnewswire.com - 1 month ago
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Amylyx Pharmaceuticals, Inc. (AMLX) and Encourages Stockholders to Learn More About the Investigation NEW YORK CITY, NY / ACCESS Newswire / May 18, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Amylyx Pharmaceuticals, Inc. ("Amylyx" or "the Company") (NASDAQ:AMLX). Investors who purchased Amylyx securities prior to November 11, 2022, and continue to hold to the present, are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/AMLX. accessnewswire.com - 1 month ago
Bronstein, Gewirtz & Grossman, LLC Encourages Amylyx Pharmaceuticals, Inc. (AMLX) Investors to Inquire about Securities Investigation NEW YORK CITY, NY / ACCESS Newswire / May 15, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Amylyx Pharmaceuticals, Inc. ("Amylyx" or "the Company") (NASDAQ:AMLX). Investors who purchased Amylyx securities prior to November 11, 2022, and continue to hold to the present, are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/AMLX. accessnewswire.com - 1 month ago
8. Profile Summary

Amylyx Pharmaceuticals, Inc. AMLX

image
COUNTRY US
INDUSTRY Biotechnology
MARKET CAP $ 461 M
Dividend Yield 0.00%
Description Amylyx Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, engages in developing various therapeutics for amyotrophic lateral sclerosis (ALS) and other neurodegenerative diseases. The company's product pipeline includes AMX0035, a dual UPR-Bax apoptosis inhibitor composed of sodium phenylbutyrate and taurursodiol for the treatment of amyotrophic lateral sclerosis. It is also developing AMX0035 for other neurodegenerative diseases. The company was founded in 2013 and is headquartered in Cambridge, Massachusetts.
Contact 43 Thorndike Street, Cambridge, MA, 02141 https://amylyx.com
IPO Date Jan. 7, 2022
Employees 123
Officers Dr. Jamie Timmons Head of Global Medical Strategy & Communications Ms. Linda A. Arsenault Chief Human Resources Officer Ms. Lindsey Allen Head of Investor Relations & Communications Mr. Joshua B. Cohen Co-Founder, Co-Chief Executive Officer & Director Mr. James M. Frates M.B.A. Chief Financial Officer Mr. Tom Holmes Chief Technical Operations Officer Ms. Tammy Sarnelli Global Head of Regulatory Affairs Dr. Machelle Manuel Ph.D. Vice President & Head of Global Medical Affairs Ms. Gina M. Mazzariello J.D. Chief Legal Officer & General Counsel Mr. Justin B. Klee Co-Founder, Co-Chief Executive Officer & Director